Immunological evaluation of rheumatoid arthritis patients treated with itolizumab. - Wikidata - wikimedia - TriplyDB

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

http://www.wikidata.org/entity/Q37138277

about

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study.CD6 as a potential target for treating multiple sclerosis Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis.The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.Targeting CD6 for the treatment of experimental autoimmune uveitis.Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells

P2860

Q33764331-2953E35A-2EDD-4DC6-BFFA-B02655DC9423 Q42177117-F4AE4155-106E-4850-813B-8170202D0456 Q42369814-42602076-CF3B-40C6-8179-0B05D6FB9152 Q48265755-744E4B92-CDF8-48D4-9DA9-8842499984C6 Q52689322-9471C02A-3F8B-4F1B-8F0A-C511C94252FA Q57816679-EA305405-CBA5-425C-B930-E0CF0B02CEE4

P2860

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

http://www.wikidata.org/entity/Q37138277

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 October 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@en

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@nl

type

label

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@en

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@nl

prefLabel

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@en

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@nl

P1433

Q37138277-91143D0A-1A87-40B9-BB15-A9A4B1A0F4DD

P1476

Q37138277-F9C7063C-BC0B-4F59-877C-2D9F46168AFF

P2093

Q37138277-142B363A-E4BB-46E0-9B2C-5FD077B14230

Q37138277-1DF2F24B-6165-4DEC-8D69-A79A6D0114D3

Q37138277-2D89AD51-5438-41AC-AA45-1F4D718DC960

Q37138277-48342A70-7E97-48FE-B88B-7AC6005EC935

Q37138277-70CC9119-FE52-4BE3-868C-929B43A243C1

Q37138277-95F7E962-22F6-4716-8FF9-60B5FBCB5948

Q37138277-CD8F698B-3094-46ED-9F09-2630D2B314F3

Q37138277-EF4EBC1C-2C31-48FE-8FDE-8AEEE6F380B6

Q37138277-FBE26E03-C57B-4C24-8B9E-4F603B404222

P2860

Q37138277-0F6DBADD-4790-4B67-9092-F71943ABA281

Q37138277-10CDCBE8-9D0B-416F-B50B-74ED2BBC318D

Q37138277-14281719-2FB8-4C0F-9947-7C450C20A1F3

Q37138277-19ACB55B-488A-46DE-8992-29775FF07D1D

Q37138277-20A89199-0623-45F3-BD93-931CCA1DF7B0

Q37138277-2164BE22-361D-479F-A97C-4EFE0A79D64D

Q37138277-23196155-01B2-415D-88B0-CBB38EB998FC

Q37138277-27A9FE7C-1B98-42EF-B8D1-BCF2DD5EDBAE

Q37138277-310DCF7D-E30A-415B-B10F-6D9B6B49ED67

Q37138277-35DBE5F6-5DDE-44B4-BA48-6880AAFFF481

P304

Q37138277-C4897673-E21D-42B9-BAF6-DEC0BBB60B59

P31

Q37138277-26BBC862-E1EF-4097-B59C-2AEFFA8CBCCA

P356

Q37138277-1ADB7344-DF6C-4BD8-9D9D-1C563891100A

P433

Q37138277-899FFB8C-EADA-45DA-8E93-1B602F9EF32E

P478

Q37138277-DA305E6A-C043-41DA-B2FD-AE5ADFA2546D

P577

Q37138277-C064A1C6-60CA-4322-83BD-6B7A3A982D89

P5875

Q37138277-ED087D9E-4A50-4AD7-BF0A-1AFD660ED3A9

P698

Q37138277-64819340-D1D4-46E4-B0A4-618AB46BEFB8

P921

Q37138277-6EB0CD4D-DC55-4A43-87FD-3D429EB65774

P932

Q37138277-EE5AF376-A615-4278-951A-35F006AFDC6B

P356

19420862.2015.1105416

P1433

Monoclonal Antibodies

P1476

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

@en

P2093

Araceli Chico

http://www.w3.org/2001/XMLSchema#string

Carmen Viada

http://www.w3.org/2001/XMLSchema#string

Dinorah Prada

http://www.w3.org/2001/XMLSchema#string

Jorge A Gómez

http://www.w3.org/2001/XMLSchema#string

Karla Fuentes

http://www.w3.org/2001/XMLSchema#string

Lazaro E Aira

http://www.w3.org/2001/XMLSchema#string

Patricia Hernández

http://www.w3.org/2001/XMLSchema#string

Zaima Mazorra

http://www.w3.org/2001/XMLSchema#string

Zuyén González

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab for rheumatoid arthritis

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

Relevance of CD6-mediated interactions in T cell activation and proliferation

Leukotrienes, mast cells, and T cells

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site

Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Multiple sclerosis susceptibility alleles in African Americans.

P304

187-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2015.1105416

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282877028

http://www.w3.org/2001/XMLSchema#string

P698

26466969

http://www.w3.org/2001/XMLSchema#string

P921

P932

4966522

http://www.w3.org/2001/XMLSchema#string